Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03576417Phase 3Active Not Recruiting

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Role: collaborator

NCT05468073Phase 2Recruiting

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Role: collaborator

NCT02957760Phase 2Unknown

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

Role: collaborator

All 3 trials loaded